CEBINA was founded with the aim of creating, nurturing, and promoting early-stage life sciences companies, to develop new medicines and cutting-edge technologies.
With decades-long experience in pharmaceutical product development and biotech entrepreneurship, our team supports our internal projects and resident companies with cutting edge facilities and tailor-made services throughout all stages of company development.
For each new project, CEBINA undertakes extensive due diligence to identify projects with the highest potential, offering attractive, de-risked opportunities for investors.
10 December 2021
CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant
14 June 2021